Introduction
Focused, high-dose radiotherapy is increasingly indicated for inoperable peripheral lung cancers (1) (2) (3) . Inoperable patients with such tumors often have moderate to severe pulmonary function impairment due to morphological changes of the diseased lung such as pulmonary emphysema, inflammatory changes, and fibrosis with our without history of previous thoracic surgery.
It is crucial to minimize the irradiation volume of the functioning lung tissue for these patients. Accordingly, it is important to predict the amount of tumor motion from clinical and radiological findings before treatment in order to determine adequate internal margins for the clinical tumor volume during radiotherapy for these patients.
Previous studies have shown that simple pulmonary function, as assessed by such parameters as vital capacity and forced vital capacity, does not have predictive value for tumor motion (4, 5) . In addition, these simple tests have recently been
shown to be inadequate for the assessment of obstructive disease, and more precise criteria of pulmonary function have been recommended instead (6) . On the other hand, morphological changes of the lung tissue around the tumor as measured using high resolution computed tomography (CT), which is known to be useful for the evaluation of obstructive, inflammatory, or fibrotic changes of the lung, may be useful Y Onodera et al.
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for predicting tumor motion (7, 8) . Therefore, in this study, we compared two parameters with respect to their efficacy in predicting tumor motion: the global standard of pulmonary function of obstructive lung disease and morphological changes of the diseased lung around the tumor. These two parameters were compared with the trajectory of the fiducial marker near the tumor as measured during real-time tumor-tracking radiotherapy (RTRT) which has been shown to be useful to estimate the amplitude of the tumor (9 -12).
Materials and Methods
After inserting a fiducial marker near the lung cancer, planning CT scan was performed while patients hold their breath at the end of expiration. We used an RTRT system that can track a gold marker in the body of a patient during actual irradiation of therapeutic beam as reported before (9, 10) . Patients were asked to relax on the treatment table, and no additional method was used to control the patient's respiration during actual radiotherapy. The advantage of RTRT is that the motion of the fiducial marker can be automatically detected by pattern recognition method during the delivery of treatment beam every 0.033 seconds (9) . The linac is gated to irradiate the tumor only when the fiducial marker is within gating window, usually ± 2.0 mm, from its planned position. Therefore, even if the magnitudes of Y Onodera et al. Three to four fiducial markers with a diameter of 1.5 mm were inserted through a bronchial fiberscope near the lung tumor (11) . Coordinates of one of the markers nearest to the tumor were recorded in log files at intervals of 0.033 s using the RTRT system (12). To measure marker movement, log files of the RTRT system were analyzed using a previously described computer program (10) .
In this study, the x, y, and z directions were consistent with the left-right, cranio-caudal, and ventro-dorsal directions, respectively. We assumed the motion of fiducial markers nearest to the tumor, usually within 1 cm from the tumor boundary, as the actual tumor motion in the x, y, and z directions. The amplitude of the fiducial marker differed patient by patient and also fluctuated even in the same patient during treatment. Therefore, we have randomly sampled respiratory cycles from each Y Onodera et al.
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patient. Mean ± standard deviation (SD) of sampling numbers of respiratory cycle was 79 ± 53 for one patient. The variations in sampling numbers of respiratory cycle were due to the length of treatment time but not due to researchers' preference.
We first measured the mean amplitude and SD of the amplitude during treatment for each patient to represent our data series. Since it is important to know the distance that the actual tumor is likely to move in the thoracic space during radiotherapy, we also measured the maximum three-dimensional amplitude during treatment for each patient.
The three-dimensional maximum movement was estimated from the following formula using the mean plus one SD of the amplitude along each direction:
estimated three-dimensional maximum movement (in mm) = .
Thus, one patient has only one "estimated three-dimensional maximum movement".
Chest CT images were acquired to plan the radiation treatment for all patients within 1 week after the insertion of gold markers and within 1 week before the start of radiotherapy. We used a 4-detector acquisition high resolution CT (Aquilion Multi Toshiba, Tokyo, Japan) for the evaluation of morphological changes of the lung tissue. In all cases, we scanned the entire lung in the exhaled position. Contrast medium was not used for the chest CT scan. All scan data were reconstructed Y Onodera et al.
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using voxels of 1 x 1 x 1 mm.
Two board-certified diagnostic radiologists independently interpreted the CT images to assess the presence of fibrotic changes. Grossly speaking, a diagnosis of fibrotic changes was made when non-segmental reticular abnormalities and ground-glass attenuation were observed in the lung parenchyma ( (Table 1 ). All patients were subjects for stereotactic hypofractionated high-dose small-field irradiation using RTRT system. The median patient age was 73 years (range, 36 to 85 years). Fifty-six patients with primary lung cancer and six patients with a metastatic lung tumor from other organs were included. The other nine patients had unknown pathology. The maximum tumor diameter ranged from 0.5 to 7.4 cm with a median of 2.7 cm. Four patients had a history of surgical lobectomy. No patients had thoracic nodal involvement in radiological examinations.
Twenty patients had normal pulmonary function. Twenty-nine patients had obstructive pulmonary dysfunction (FEV1/FVC < 70%), six patients had constrictive dysfunction (%VC < 80%), and sixteen patients had mixed dysfunction. The mean ± standard deviation values of FEV1/FVC and %VC were 62.5 ± 16.9% and 94.9 ± 25.7%, respectively. There was a significant negative correlation between FEV1/FVC and log %LAV (correlation coefficient, -0.494. p<0.0001) confirming that %LAV has morphometric value for pulmonary emphysema (Fig. 2) .
The mean ± SD of mean amplitudes among the 71 patients was 3.7 ± 4.6, 6.7 ± 6.2, and 4.4 ± 4.8 mm along right-left, cranio-caudal, and antero-posterior directions, respectively. The mean ± SD of SD of amplitudes among the 71 patients was 1.2 ± 2.2 mm, 1.8 ± 2.8 mm, and 1.1 ± 1.5 mm along each direction, respectively.
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The mean plus one SD of the amplitude of the fiducial marker among 71 patients distributed from 0.2 to 32.1 mm, from 0.2 to 31.2 mm, and from 0.5 to 34.8 mm along
right-left, cranio-caudal, and antero-posterior directions, respectively. The estimated three-dimensional maximum movements were calculated using these data for each patient. The median and range of estimated three-dimensional maximum movements of 71 patients was 11.9 mm (1.79 mm -50.38 mm).
The relationship between each factor and the estimated three-dimensional maximum movement, which we used as the surrogate of the tumor motion in this study, is shown in Table 2 It is well known that the diaphragmatic motion often decreases in patients with emphysematous lung (17) . Tumors in the normal lung move mostly in a cranio-caudal direction due to diaphragmatic motion (18) . We therefore hypothesized that pulmonary emphysema could be a cause of reduced tumor motion.
We are certain that %LAV is a reasonable parameter to estimate the severity of Y Onodera et al.
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emphysema since %LAV was significantly associated with FEV1.0/FVC in this study, and such an association has also been suggested by other authors (13, 15) .
However, the present study showed no significant reduction in tumor motion with the increase in %LAV. Recent studies have shown that the diaphragm sometimes exhibits so-called "paradoxical" motion. (17, 19) . Emphysema may cause complex tumor motion resembling the complex motion of the diaphragm, rather than simply causing a reduction in tumor motion.
We have previously shown that neither VC alone nor FEV 1 alone was associated with tumor motion (5). However, pulmonologists suggested us that %VC and FEV 1 /FVC should be used instead of VC and FEV 1 to assess its pathological meaning (6) . We therefore used these combined parameters in the present study, but found that the variables still had no significant value for predicting tumor motion even in this form.
The present results suggested usefulness and limitation of CT assessment before radiotherapy in general. Moreover, as we published previously (18), the speed and amplitude of the tumor motion was variable even in the same patient at different treatment day. In other words, assessment of tumor motion at the initial treatment day may not be applicable in the second treatment day. Stereotactic body frame Y Onodera et al.
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and rhythm generators were shown to be not useful to reduce these uncertainties in a recent study (20) . Image-guided radiotherapy using on-board cone-beam CT (21) Y Onodera et al. 
FEV1/FVC

